Clinically Shown Effectiveness against the Herpes Virus

Dynamiclear Clinical Evidence

Clinically Shown Effectiveness

The safety and effectiveness of the Dynamiclear Antiviral Gel is supported by multiple clinical studies.

These clinical studies demonstrate the significant potential of Dynamiclear as an effective topical antiviral agent against herpes.

Proven Efficacy and Integrity

In 2006 Dynamiclear sponsored a Clinical Trial to prove what the staff and clients of the Health Care Practice of Dr John Spurge ND in Queensland Australia has been witnessing for over a decade – that Dynamiclear is a potent and very promising therapy for HSV-1 and HSV-2.

In February 2012 this study became officially listed in the PubMed database of clinical trials.

The Dynamiclear Clinical Trial was conducted on adult patients suffering from Herpes simplex infections Type I and Type II. It was a multicenter, randomized, prospective, open label study to evaluate the safety, tolerability and efficacy of Dynamiclear as a treatment for Herpes simplex (Type 1 and 2) in adult patients.

During the study the Dynamiclear group experienced significantly improved relief of symptoms after only a single application – including fast clearance of redness, burning, stinging, itching and blisters associated with genital herpes and cold sores (oral herpes). There were no adverse events reported in this study.

The application of Dynamiclear lead to earlier crusting and healing of the lesions, erythema [redness] and pain. There were no reported clinically significant adverse events… The trial clearly showed that compared to a commercially available 5% acyclovir cream, Dynamiclear was effective in relieving symptoms of genital and orofacial HSV lesions without significant adverse eventsAssociate Professor John W Quin

Professor Quin is the Director of Clinical Immunology, Sexual Health and HIV Medicine at the Liverpool Hospital in Sydney Australia.

In the clinical trial 63.9% of all users in the Dynamiclear group experienced complete healing of their HSV blisters after 72 hours of a single application of Dynamiclear, compared to only 23.4% in the topical Acyclovir comparator control group.

After 8 days the majority of Dynamiclear users had complete disappearance of their blisters (90.2%) compared to just over half of users in the Acyclovir group (59.3%).

Download the Dynamiclear Clinical Trial peer-review publication as featured in the prestigious Journal of Drugs and Dermatology (New York), February 2012, Issue 11, Volume 2.

Maryland University Study proves potent potential of the Dynamiclear Antiviral Gel active ingredients against HSV.

In an independent, peer-reviewed and published Maryland University clinical study, it was demonstrated that the Dynamiclear active (Cupric ions) reduced colony forming Herpes simplex virus HSV cells from 100% to less than 10% in 30 minutes.

Fast Acting Molecule

The study shows how the active in Dynamiclear immediately goes into action destroying the Herpes virus colonies on contact, as well as the host cell harboring the virus. Dynamiclear acts like a spear, puncturing the host cell and the DNA of the Herpes virus.